Jynneos

Jynneos is a vaccine used to prevent smallpox, monkeypox, and horsepox infections. It was developed by Bavarian Nordic, a Danish biotechnology company, in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID). The vaccine was previously known as ACAM2000 and Imvamune before being rebranded as Jynneos under its new manufacturer-based name.

Jynneos is a live vaccine, which means that it contains a weakened form of the virus. The vaccine is administered via injection into the skin, and two doses are given to provide immunity. The vaccine has shown to be highly effective in preventing infections, with a 95% efficacy rate in preventing monkeypox.

The development of Jynneos began in 2002, with funding provided by the US NIAID. The vaccine has undergone extensive testing and has been shown to be safe and effective in protecting against smallpox, monkeypox, and horsepox. The FDA granted the vaccine its approval in 2019 for the prevention of smallpox and monkeypox.

Jynneos is considered a crucial tool in preventing the spread of diseases such as smallpox and monkeypox. In 2019, the US Centers for Disease Control and Prevention (CDC) stockpiled millions of doses of the vaccine, given the high risk of future outbreaks. The use of Jynneos to prevent smallpox and other poxvirus infections is a testament to the importance of vaccine research and development in protecting public health.